ALS Gene Therapy: Early Promise Emerges

An experimental gene therapy program at Columbia University is showing early signs that it may be able to delay or prevent the onset of Amyotrophic Lateral Sclerosis (ALS) in people who carry a specific inherited mutation, according to researchers involved in the work. The approach is aimed at a mutated form of the FUS gene, which is described as important for normal nerve cell function.

Officials leading the effort said the results so far point to the possibility of intervening before symptoms progress into full disease.

One participant, scientist Jeff Vierstra, has received the treatment for three years and has not developed ALS, despite a family history tied to FUS gene-linked ALS. The disease previously killed his mother and two sisters, and he tested positive for the same FUS mutation. After early neurological abnormalities were detected, he began receiving spinal infusions of the experimental therapy, the researchers said.

Columbia University neurologist Dr. Neil Shneider, who is leading the trial, described the development as meaningful because it suggests a path toward changing how ALS is managed in genetically defined cases. In the account provided, Vierstra’s muscle abnormalities that had been observed earlier returned to normal after one year of treatment. He has also lived beyond the lifespan reached by many affected relatives, according to the information shared about his family history.

The treatment has also been used in Vierstra’s sisters, and it was reported to have extended their lives. The source material does not provide specific timelines for their treatment courses or the degree of extension, and it does not describe the size of the trial or how outcomes are being measured across participants. Those gaps leave uncertainty about how broadly the early signals can be applied beyond the individuals described.

Researchers involved in the work said they are now trying to broaden the gene-based strategy to other rare genetic forms of ALS. The source material notes that roughly 10-15% of ALS cases are genetic, and that about two-thirds of those genetic cases are familial. That framing underscores why a targeted therapy could matter for a defined subset of patients, while also highlighting that most ALS cases fall outside the inherited category described here.

For global markets and health systems, the story is closely tied to how advanced therapies move from experimental programs into scalable care. The information provided points to a highly specialized delivery method—spinal infusions—and a mutation-specific target, both of which can shape cost, manufacturing needs, and access if the approach expands.

At the same time, the work remains experimental, and the source material does not include comparative data, longer-term durability, or broader trial results, leaving key questions unresolved as researchers pursue expansion to other genetic ALS forms.